A Phase 1/2 Study of Gemcitabine and Nab-paclitaxel Plus Avutometinib and Defactinib in People With Advanced Pancreatic Cancer


Full Title

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas


Researchers want to find the best doses of 4 drugs to use together for treating advanced pancreatic cancer. The 4 drugs are defactinib, VS-6766 (avutometinib), gemcitabine, and nab-paclitaxel. The people in this study have pancreatic cancer that metastasized (spread) and has not yet been treated.

Defactinib and avutometinib disrupt signals that tell cancer cells to divide. They may work especially well against pancreatic cancers with a mutation in the KRAS gene. Both drugs are taken orally (by mouth).

Gemcitabine and nab-paclitaxel are chemotherapy drugs routinely used as the first treatments for pancreatic cancer. They are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have metastatic pancreatic cancer that has not yet been treated.
  • Have completed any prior pancreatic cancer treatments at least 1 year before you learned your cancer had spread.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Anna Varghese’s office at 646-888-4308.




Phase I/II (phases 1 and 2 combined)



ClinicalTrials.gov ID